CMPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Checkmate Pharmaceuticals's quarterly net PPE increased from Sep. 2021 ($0.67 Mil) to Dec. 2021 ($0.78 Mil) but then declined from Dec. 2021 ($0.78 Mil) to Mar. 2022 ($0.74 Mil).
Checkmate Pharmaceuticals's annual net PPE stayed the same from Dec. 2019 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.78 Mil).
The historical data trend for Checkmate Pharmaceuticals's Property, Plant and Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkmate Pharmaceuticals Annual Data | |||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | |||||
Property, Plant and Equipment | - | - | - | 0.78 |
Checkmate Pharmaceuticals Quarterly Data | ||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Property, Plant and Equipment | Get a 7-Day Free Trial | - | 0.37 | 0.67 | 0.78 | 0.74 |
Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.
Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.
Some of the most common parts of property, plant, and equipment are:
Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:
There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.
The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.
For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.
All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.
The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.
Checkmate Pharmaceuticals (NAS:CMPI) Property, Plant and Equipment Explanation
A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.
Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.
Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.
Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
Venbio Global Strategic Fund Ii L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Alan Bash | director, officer: Chief Executive Officer | C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Jon Marc Wigginton | director | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Joy Yan | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Arthur M Krieg | director, officer: Chief Scientific Officer | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Robert Dolski | officer: Chief Financial Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Barry Labinger | director, officer: President and CEO | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Peter Colabuono | director | C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025 |
Oren Isacoff | director | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Karen Brennan | officer: Chief Operating Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Kleem Chaudhary | officer: Chief Business Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Venbio Global Strategic Gp Ii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Gp Ii, Ltd. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Nilesh Kumar | director | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
From GuruFocus
By PRNewswire PRNewswire • 06-15-2022
By GuruFocus Research GuruFocus Editor • 05-18-2022
By PRNewswire PRNewswire • 04-19-2022
By PRNewswire PRNewswire • 06-16-2022
By PRNewswire PRNewswire • 05-27-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By GuruFocusNews GuruFocusNews • 05-12-2022
By PRNewswire PRNewswire • 05-17-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By PRNewswire PRNewswire • 04-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.